Teva Pharmaceutical Industries Ltd (TEVA)

[genisi]

TEVA ANNOUNCES APPROVAL OF AMLODIPINE BESYLATE TABLETS

Jerusalem, Israel, June 29, 2007 – Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA)announced today that the U. S. Food and Drug Administration (FDA) has granted approval for the company’s ANDA for Amlodipine Besylate Tablets, 2.5 mg, 5 mg and 10 mg. Shipment of the product will begin shortly. Teva’s Amlodipine Besylate Tablets are the AB-rated generic equivalent of Pfizer’s Norvasc®
Tablets, and are indicated for treatment of hypertension, chronic stable angina and vasospastic angina. Mylan has sued the FDA arguing that its 180-day exclusivity blocks other final approvals
until September, 2007. Total annual sales of this product are approximately $2.8 billion for the twelve months ended
March 31, 2007, based on IMS sales data.